Overcoming Challenges in Oligonucleotide Therapeutics Analysis: A Novel Nonion Pair Approach

Yoshiharu Hayashi1, Yuchen Sun2

  • 1Bioanalysis Research Department, CMIC Pharma Science Co., Ltd., Hyogo 677-0032, Japan.

Insights

A new non-ion pairing, reverse-phase LC-MS method simplifies oligonucleotide therapeutic bioanalysis. This reliable, cost-effective approach overcomes limitations of traditional methods for analyzing these promising drugs.

Area of Science:

  • Analytical Chemistry
  • Pharmaceutical Sciences
  • Biotechnology

Background:

  • Oligonucleotide therapeutics (OT) show promise for intractable diseases.
  • Liquid chromatography-mass spectrometry (LC-MS) is crucial for OT characterization and quantification.
  • Traditional ion-pairing, reverse-phase (IP-RP) LC-MS methods for OT bioanalysis have limitations like memory and ion suppression effects.

Purpose of the Study:

  • To develop a novel reverse-phase LC-MS (RP-LC-MS) method for oligonucleotide therapeutic bioanalysis.
  • To eliminate the need for ion-pairing reagents in OT bioanalysis.
  • To establish a versatile, sensitive, and reliable method for quantifying various oligonucleotides.

Main Methods:

  • Development of a non-ion pairing, reverse-phase LC-MS (nonIP-RP-LC-MS) method.
  • Utilized ammonium bicarbonate as a key component for successful method implementation.
  • Assessed method versatility across natural and chemically modified oligonucleotides; determined sensitivity using reconstituted plasma samples.

Main Results:

  • Successfully developed and validated a nonIP-RP-LC-MS method for OT bioanalysis.
  • Ammonium bicarbonate was identified as essential for the method's efficacy.
  • The method demonstrated high versatility for diverse oligonucleotide types and achieved a lower limit of quantification of 0.5-1 ng/mL in plasma.

Conclusions:

  • The developed nonIP-RP-LC-MS method provides an improved approach for OT bioanalysis.
  • This method is easy, reliable, and cost-effective, overcoming limitations of traditional IP-RP-LC-MS.
  • It offers a versatile platform for the quantification of various oligonucleotide therapeutics in biological matrices.